Clinical characteristics of AML patients
Sample . | Age, years . | Sex . | FAB . | WBC . | BM/PB . | Disease status . | Risk category . | Cytogenetics . | Flt3 mutn . | %Blasts (PB) . | %Blasts (BM) . |
---|---|---|---|---|---|---|---|---|---|---|---|
AML 1 | 61 | F | M1 | 82.9 | BM | Untreated | I | t(1;7) | NA | 87 | 90 |
AML 2 | 47 | F | M4 | 50.8 | PB | Untreated | B | inv(16) | Neg | 67 | 90 |
AML 3 | 61 | M | NA | 1.8 | PB | Untreated | I | +13, +21 | NA | 26 | |
AML 4 | 56 | F | M2 | 38.8 | PB | Untreated | B | inv(16), +8 | NA | 63 | 44 |
AML 5 | 69 | M | NA | 18.2 | PB | Untreated | P | del(5q), inv(1q), −17 | NA | 4 | 18 |
AML 6 | 54 | M | M4 | 14.2 | PB | Untreated | P | Complex | Neg | 3 | 60 |
AML 7 | 54 | M | M4 | 14.2 | BM | Untreated | P | Complex | Neg | 3 | 60 |
AML 8 | 40 | F | NA | 8.6 | PB | Relapsed | B | t(8;21); - | NA | 80 | |
AML 9 | 39 | F | M2 | 6.5 | BM | Untreated | B | t(8;21), | NA | 32 | 40 |
AML 10 | 51 | M | NA | 13.4 | BM | Untreated | B | Inv(16), +8, +21 | NA | 70 | 75 |
AML 11 | 57 | M | M4 | 82.8 | PB | Relapsed | B | t(16;16), +21, t+22 | NA | 94 | 67 |
AML 12 | 70 | M | NA | 114.7 | PB | Relapsed | I | t(1;7), t(14;15) | NA | 90 | |
AML 13 | 71 | M | NA | 32.4 | PB | Relapsed | I | del(20) | NA | 90 | 64 |
AML 14 | 62 | F | M6 | 2.7 | BM | Persistent | P | Complex | NA | 20 | 60 |
AML 15 | 66 | F | NA | 8.9 | BM | Relapsed | P | Complex | NA | 1 | 90 |
AML 16 | 63 | F | M6 | 1.5 | BM | Persistent | P | Complex | NA | 4 | 33 |
AML 17 | 58 | M | M4 | 27.3 | PB | Relapsed | I | Normal | NA | 89 | |
AML 18 | 81 | F | NA | 20.5 | BM | Refractory | P | Complex | NA | 62 | 72 |
AML 19 | 23 | M | M3 | 80.7 | PB | Untreated | I | t(7;11) | Neg | 28 | |
AML 20 | 41 | M | M4 | 11.9 | BM | Relapsed | P | Complex | NA | 5 | 62 |
AML 21 | 83 | F | NA | 31.1 | BM | Persistent | I | Normal | NA | 33 | 33 |
AML 22 | 76 | M | NA | 6.9 | BM | Untreated | I | Normal | NA | 25 | 64 |
AML 23 | 42 | M | NA | 5.4 | PB | Persistent | I | inv(13), del(3) | NA | 80 | |
AML 24 | 32 | M | M5 | 22.2 | PB | Induction failure | P | t(9;11), del(9p) | Neg | 61 | |
AML 25 | 64 | F | M0 | 6.2 | PB | Persistent | I | t(2;8), t(3;12;7), 3q26.2 | NA | 96 | |
AML 26 | 41 | M | M4 | 30.5 | BM | Relapsed | P | Complex | NA | 17 | 53 |
AML 27 | 74 | F | NA | 63.3 | PB | Untreated | B | Normal | Neg | 76 | |
AML 28 | 74 | F | M4 | 10.5 | PB | Persistent | P | Complex | NA | 74 | |
AML 29 | 46 | F | NA | 3.2 | PB | Relapsed | I | Trisomy 8 | NA | 3 | 30 |
AML 30 | 81 | F | NA | 30.42 | PB | Persistent | P | Complex | NA | 33 | |
AML 31 | 44 | F | NA | 12.1 | PB | Relapsed | I | del(17p), dic(11;7), | NA | 47 | 0 |
AML 32 | 74 | F | NA | 1.9 | BM | Persistent | I | Trisomy 8, Tetrasomy 8 | NA | 1 | 21.5 |
AML 33 | 31 | F | NA | 63.6 | PB | Relapsed | P | del(11q),t(3;18) | Pos | 81 | |
AML 34 | 56 | F | NA | 7.7 | BM | Untreated | I | Normal | NA | 28 | 32.5 |
AML 35 | 69 | M | M4 | 22 | PB | Untreated | P | +8, del(13q) | Pos | 75 | |
AML 36 | 46 | F | M1 | 30 | PB | Relapsed | P | del(10), t(10;11) | Pos | 82 | |
AML 37 | 58 | M | NA | 12.1 | PB | Induction failure | I | t(3;6),del(7) | Pos | 60 | |
AML 38 | 42 | F | M3 | 9.1 | PB | Untreated | B | t(15;17) | Neg | 64 | 95 |
AML 39 | 28 | M | NA | 49.76 | PB | Relapsed | I | Normal | NA | 61 | |
AML 40 | 58 | F | M1 | 21.8 | PB | Untreated | I | Normal | NA | 56 | 74 |
AML 41 | 37 | M | M4/M5 | 30.5 | PB | Induction failure | P | Normal | Pos | 24 | |
AML 42 | 58 | F | NA | 15.4 | PB | Relapsed | P | inv(3q), add(16) | NA | 58 | |
AML 43 | 61 | F | M2 | 8.4 | PB | Persistence | P | Complex | NA | 63 | |
AML 44 | 59 | F | M5 | 22.7 | PB | Untreated | B | Normal | Neg | 7 | 50 |
AML 45 | 55 | F | NA | 11 | PB | Relapsed | P | Inv(3), add (16) | Neg | 57 | |
AML 46 | 55 | M | M1/M2 | 136.4 | PB | Persistent | B | Normal | Neg | 94 | |
AML 47 | 24 | M | NA | 4.3 | BM | Persistent | I | Two clonal abnormalities t(7;11) | NA | 0 | 1 |
AML 48 | 56 | M | M1/M2 | 43.2 | PB | Untreated | I | Trisomy 4 | NA | 90 | |
AML 49 | 21 | F | NA | 71.1 | PB | Relapsed | P | Complex | Neg | 93 | |
AML 50 | 83 | M | 6.5 | PB | Untreated | P | Complex abnormalities, | NA | 53 | ||
AML 51 | 23 | M | M1 | 1.5 | PB | Refectory | P | Complex | NA | 14 | |
AML 52 | 74 | F | NA | 4.5 | PB | Refectory | P | Normal cytogenetics, | NA | 96 | |
AML 53 | 64 | M | NA | 15.4 | BM | Untreated | P | t(9;22) | NA | 15 | 22.5 |
AML 54 | 61 | M | NA | 7.6 | PB | Induction failure | P | Complex abnormalities, including del(5q), del(6q), del(17p) | NA | 72 | 80 |
AML 55 | 57 | M | M-4 | 82.8 | BM | Relapsed | B | t(16:16), trisomy 21, trisomy 22 | NA | 94 | 70 |
AML 56 | 73 | M | M-0 | 42.5 | BM | Untreated | P | del(5q), trisomy 8, trisomy 13, del(17p) | Neg | 87 | 95 |
AML 57 | 38 | M | NA | 1.8 | BM | Relapsed | I | Normal Cytogenetic | NA | 0 | 20 |
AML 58 | 30 | F | NA | 12.7 | PB | Untreated | I | Normal Cytogenetic | NA | 75 | ND |
AML 59 | 68 | M | NA | 8.4 | BM | Relapsed | I | Trisomy 13, Trisomy 21 | Neg | 10 | 58 |
AML 60 | 67 | M | NA | 16.5 | BM | Persistent | I | Trisomy 8, Tetrasomy 8 | NA | 75 | 84 |
AML 61 | 73 | F | NA | 22.7 | BM | Untreated | I | Trisomy 8, Tetrasomy 8 | NA | 2 | 23 |
AML 62 | 23 | F | NA | 64.8 | PB | Relapsed | P | Complex abnormalities, including del(11p) | Pos | 84 | ND |
AML 63 | 47 | M | M-4 | 31.3 | PB | Relapsed | P | Complex abnormalities in 3 cell lines | NA | 91 | ND |
AML 64 | 79 | F | NA | 1.9 | PB | Refectory | P | monosomy 7, trisomy 21 | NA | 0 | ND |
AML 65 | 74 | F | M4 | 5.3 | BM | Relapsed | P | Complex abnormalities, including monosomy 7, del (7q), RUNX!, MLL loss, | NA | 37 | 86 |
AML 66 | 61 | F | NA | 44.7 | PB | Untreated | P | Complex abnormalities, | NA | 51 | 80 |
AML 67 | 47 | M | M-0 | 5.9 | PB | Relapsed | P | Complex abnormalities, including monosomy 8, loss of ABL1/ASS | NA | 54 | ND |
AML 68 | 28 | M | NA | 49.7 | PB | Relapsed | I | Normal Cytogenetic | NA | 61 | ND |
AML 69 | 57 | M | NA | 73.3 | Leukocytes | Relapsed | P | Massive hyperdiploidy (> 50 chromosomes) | Neg | 93 | ND |
AML 70 | 74 | F | NA | 23.6 | BM | Persistent | I | Trisomy 8, Tetrasomy 8 | NA | 12 | 47 |
AML 71 | 38 | M | M4/M5 | 1.3 | PB | Induction failure/refractory | P | Trisomy 8, del(9q), t(2;18), trisomy 13 | Pos | 41 | 8 |
AML 72 | 48 | F | NA | 14.9 | PB | Persistence | P | del(6), t(10;11) | Pos | 61 | 60 |
Sample . | Age, years . | Sex . | FAB . | WBC . | BM/PB . | Disease status . | Risk category . | Cytogenetics . | Flt3 mutn . | %Blasts (PB) . | %Blasts (BM) . |
---|---|---|---|---|---|---|---|---|---|---|---|
AML 1 | 61 | F | M1 | 82.9 | BM | Untreated | I | t(1;7) | NA | 87 | 90 |
AML 2 | 47 | F | M4 | 50.8 | PB | Untreated | B | inv(16) | Neg | 67 | 90 |
AML 3 | 61 | M | NA | 1.8 | PB | Untreated | I | +13, +21 | NA | 26 | |
AML 4 | 56 | F | M2 | 38.8 | PB | Untreated | B | inv(16), +8 | NA | 63 | 44 |
AML 5 | 69 | M | NA | 18.2 | PB | Untreated | P | del(5q), inv(1q), −17 | NA | 4 | 18 |
AML 6 | 54 | M | M4 | 14.2 | PB | Untreated | P | Complex | Neg | 3 | 60 |
AML 7 | 54 | M | M4 | 14.2 | BM | Untreated | P | Complex | Neg | 3 | 60 |
AML 8 | 40 | F | NA | 8.6 | PB | Relapsed | B | t(8;21); - | NA | 80 | |
AML 9 | 39 | F | M2 | 6.5 | BM | Untreated | B | t(8;21), | NA | 32 | 40 |
AML 10 | 51 | M | NA | 13.4 | BM | Untreated | B | Inv(16), +8, +21 | NA | 70 | 75 |
AML 11 | 57 | M | M4 | 82.8 | PB | Relapsed | B | t(16;16), +21, t+22 | NA | 94 | 67 |
AML 12 | 70 | M | NA | 114.7 | PB | Relapsed | I | t(1;7), t(14;15) | NA | 90 | |
AML 13 | 71 | M | NA | 32.4 | PB | Relapsed | I | del(20) | NA | 90 | 64 |
AML 14 | 62 | F | M6 | 2.7 | BM | Persistent | P | Complex | NA | 20 | 60 |
AML 15 | 66 | F | NA | 8.9 | BM | Relapsed | P | Complex | NA | 1 | 90 |
AML 16 | 63 | F | M6 | 1.5 | BM | Persistent | P | Complex | NA | 4 | 33 |
AML 17 | 58 | M | M4 | 27.3 | PB | Relapsed | I | Normal | NA | 89 | |
AML 18 | 81 | F | NA | 20.5 | BM | Refractory | P | Complex | NA | 62 | 72 |
AML 19 | 23 | M | M3 | 80.7 | PB | Untreated | I | t(7;11) | Neg | 28 | |
AML 20 | 41 | M | M4 | 11.9 | BM | Relapsed | P | Complex | NA | 5 | 62 |
AML 21 | 83 | F | NA | 31.1 | BM | Persistent | I | Normal | NA | 33 | 33 |
AML 22 | 76 | M | NA | 6.9 | BM | Untreated | I | Normal | NA | 25 | 64 |
AML 23 | 42 | M | NA | 5.4 | PB | Persistent | I | inv(13), del(3) | NA | 80 | |
AML 24 | 32 | M | M5 | 22.2 | PB | Induction failure | P | t(9;11), del(9p) | Neg | 61 | |
AML 25 | 64 | F | M0 | 6.2 | PB | Persistent | I | t(2;8), t(3;12;7), 3q26.2 | NA | 96 | |
AML 26 | 41 | M | M4 | 30.5 | BM | Relapsed | P | Complex | NA | 17 | 53 |
AML 27 | 74 | F | NA | 63.3 | PB | Untreated | B | Normal | Neg | 76 | |
AML 28 | 74 | F | M4 | 10.5 | PB | Persistent | P | Complex | NA | 74 | |
AML 29 | 46 | F | NA | 3.2 | PB | Relapsed | I | Trisomy 8 | NA | 3 | 30 |
AML 30 | 81 | F | NA | 30.42 | PB | Persistent | P | Complex | NA | 33 | |
AML 31 | 44 | F | NA | 12.1 | PB | Relapsed | I | del(17p), dic(11;7), | NA | 47 | 0 |
AML 32 | 74 | F | NA | 1.9 | BM | Persistent | I | Trisomy 8, Tetrasomy 8 | NA | 1 | 21.5 |
AML 33 | 31 | F | NA | 63.6 | PB | Relapsed | P | del(11q),t(3;18) | Pos | 81 | |
AML 34 | 56 | F | NA | 7.7 | BM | Untreated | I | Normal | NA | 28 | 32.5 |
AML 35 | 69 | M | M4 | 22 | PB | Untreated | P | +8, del(13q) | Pos | 75 | |
AML 36 | 46 | F | M1 | 30 | PB | Relapsed | P | del(10), t(10;11) | Pos | 82 | |
AML 37 | 58 | M | NA | 12.1 | PB | Induction failure | I | t(3;6),del(7) | Pos | 60 | |
AML 38 | 42 | F | M3 | 9.1 | PB | Untreated | B | t(15;17) | Neg | 64 | 95 |
AML 39 | 28 | M | NA | 49.76 | PB | Relapsed | I | Normal | NA | 61 | |
AML 40 | 58 | F | M1 | 21.8 | PB | Untreated | I | Normal | NA | 56 | 74 |
AML 41 | 37 | M | M4/M5 | 30.5 | PB | Induction failure | P | Normal | Pos | 24 | |
AML 42 | 58 | F | NA | 15.4 | PB | Relapsed | P | inv(3q), add(16) | NA | 58 | |
AML 43 | 61 | F | M2 | 8.4 | PB | Persistence | P | Complex | NA | 63 | |
AML 44 | 59 | F | M5 | 22.7 | PB | Untreated | B | Normal | Neg | 7 | 50 |
AML 45 | 55 | F | NA | 11 | PB | Relapsed | P | Inv(3), add (16) | Neg | 57 | |
AML 46 | 55 | M | M1/M2 | 136.4 | PB | Persistent | B | Normal | Neg | 94 | |
AML 47 | 24 | M | NA | 4.3 | BM | Persistent | I | Two clonal abnormalities t(7;11) | NA | 0 | 1 |
AML 48 | 56 | M | M1/M2 | 43.2 | PB | Untreated | I | Trisomy 4 | NA | 90 | |
AML 49 | 21 | F | NA | 71.1 | PB | Relapsed | P | Complex | Neg | 93 | |
AML 50 | 83 | M | 6.5 | PB | Untreated | P | Complex abnormalities, | NA | 53 | ||
AML 51 | 23 | M | M1 | 1.5 | PB | Refectory | P | Complex | NA | 14 | |
AML 52 | 74 | F | NA | 4.5 | PB | Refectory | P | Normal cytogenetics, | NA | 96 | |
AML 53 | 64 | M | NA | 15.4 | BM | Untreated | P | t(9;22) | NA | 15 | 22.5 |
AML 54 | 61 | M | NA | 7.6 | PB | Induction failure | P | Complex abnormalities, including del(5q), del(6q), del(17p) | NA | 72 | 80 |
AML 55 | 57 | M | M-4 | 82.8 | BM | Relapsed | B | t(16:16), trisomy 21, trisomy 22 | NA | 94 | 70 |
AML 56 | 73 | M | M-0 | 42.5 | BM | Untreated | P | del(5q), trisomy 8, trisomy 13, del(17p) | Neg | 87 | 95 |
AML 57 | 38 | M | NA | 1.8 | BM | Relapsed | I | Normal Cytogenetic | NA | 0 | 20 |
AML 58 | 30 | F | NA | 12.7 | PB | Untreated | I | Normal Cytogenetic | NA | 75 | ND |
AML 59 | 68 | M | NA | 8.4 | BM | Relapsed | I | Trisomy 13, Trisomy 21 | Neg | 10 | 58 |
AML 60 | 67 | M | NA | 16.5 | BM | Persistent | I | Trisomy 8, Tetrasomy 8 | NA | 75 | 84 |
AML 61 | 73 | F | NA | 22.7 | BM | Untreated | I | Trisomy 8, Tetrasomy 8 | NA | 2 | 23 |
AML 62 | 23 | F | NA | 64.8 | PB | Relapsed | P | Complex abnormalities, including del(11p) | Pos | 84 | ND |
AML 63 | 47 | M | M-4 | 31.3 | PB | Relapsed | P | Complex abnormalities in 3 cell lines | NA | 91 | ND |
AML 64 | 79 | F | NA | 1.9 | PB | Refectory | P | monosomy 7, trisomy 21 | NA | 0 | ND |
AML 65 | 74 | F | M4 | 5.3 | BM | Relapsed | P | Complex abnormalities, including monosomy 7, del (7q), RUNX!, MLL loss, | NA | 37 | 86 |
AML 66 | 61 | F | NA | 44.7 | PB | Untreated | P | Complex abnormalities, | NA | 51 | 80 |
AML 67 | 47 | M | M-0 | 5.9 | PB | Relapsed | P | Complex abnormalities, including monosomy 8, loss of ABL1/ASS | NA | 54 | ND |
AML 68 | 28 | M | NA | 49.7 | PB | Relapsed | I | Normal Cytogenetic | NA | 61 | ND |
AML 69 | 57 | M | NA | 73.3 | Leukocytes | Relapsed | P | Massive hyperdiploidy (> 50 chromosomes) | Neg | 93 | ND |
AML 70 | 74 | F | NA | 23.6 | BM | Persistent | I | Trisomy 8, Tetrasomy 8 | NA | 12 | 47 |
AML 71 | 38 | M | M4/M5 | 1.3 | PB | Induction failure/refractory | P | Trisomy 8, del(9q), t(2;18), trisomy 13 | Pos | 41 | 8 |
AML 72 | 48 | F | NA | 14.9 | PB | Persistence | P | del(6), t(10;11) | Pos | 61 | 60 |
B, better risk; F, female; FAB, French-American-British classification; FLT3 mutn, FLT3-ITD internal tandem duplication mutation; I, Intermediate risk; M, male; NA, nonavailable; Neg, negative; P, poor risk; Pos, positive; WBC, white blood cell count (cells per microliter).